1
Clinical Trials associated with HLA-A-0206 restricted URLC10 peptides(Shiga University)Phase I Study of Cancer Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*02 (URLC10) in Patients With Non-small Cell Lung Cancer Refractory to Standard Therapy
The purpose of this study is to evaluate the safety, tolerability, immune response and clinical efficacies of HLA-A*0201 or HLA-A*0206 restricted epitope peptides URLC10 emulsified with Montanide ISA 51 for advanced non-small cell lung cancers.
100 Clinical Results associated with HLA-A-0206 restricted URLC10 peptides(Shiga University)
100 Translational Medicine associated with HLA-A-0206 restricted URLC10 peptides(Shiga University)
100 Patents (Medical) associated with HLA-A-0206 restricted URLC10 peptides(Shiga University)
100 Deals associated with HLA-A-0206 restricted URLC10 peptides(Shiga University)